Liposomal Iron for Iron Deficiency Anemia in Women of Reproductive Age: Review of Current Evidence

Biniwale, Parag; Pal, Bhaskar; Sundari, Tripura; Mandrupkar, Gorakh; Datar, Nikhil; Khurana, Amandeep; Qamra, Amit; Motlekar, Salman; Jain, Rishi

doi:10.4236/ojog.2018.811100

Cited by 11 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomal carriage favors lesser exposure to gastric contents and allows targeted delivery and the administration of lower doses due to direct absorption into the bloodstream without the need for protein carriers. 81 …”

Section: Discussionmentioning

confidence: 99%

Iron Deficiency Anemia in Pregnancy: Novel Approaches for an Old Problem

Garzon

Cacciato

Certelli³

et al. 2020

Oman Med J

View full text Add to dashboard Cite

Iron needs increase exponentially during pregnancy to meet the increased demands of the fetoplacental unit, to expand maternal erythrocyte mass, and to compensate for iron loss at delivery. In more than 80% of countries in the world, the prevalence of anemia in pregnancy is > 20% and could be considered a major public health problem. The global prevalence of anemia in pregnancy is estimated to be approximately 41.8%. Undiagnosed and untreated iron deficiency anemia (IDA) can have a great impact on maternal and fetal health. Indeed, chronic iron deficiency can affect the general wellbeing of the mother and leads to fatigue and reduced working capacity. Given the significant adverse impact on maternal-fetal outcomes, early recognition and treatment of this clinical condition is fundamental. Therefore, the laboratory assays are recommended from the first trimester to evaluate the iron status. Oral iron supplementation is the first line of treatment in cases of mild anemia. However, considering the numerous gastrointestinal side effects that often lead to poor compliance, other therapeutic strategies should be evaluated. This review aims to provide an overview of the current evidence about the management of IDA in pregnancy and available treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Iron Deficiency Anemia in Pregnancy: Novel Approaches for an Old Problem

Garzon

Cacciato

Certelli³

et al. 2020

Oman Med J

View full text Add to dashboard Cite

show abstract

“…Oral iron salts are absorbed via divalent metal transporter 1 (DMT-1). Conventional forms of oral iron salts have this advantage of cost effectiveness and extensive availability, nonetheless, the constraint of GI intolerance, especially metallic after taste, stands still [10, 12]. In an Ugandian study, only 12% pregnant women were compliant to their iron supplementation [9].…”

Section: Discussionmentioning

confidence: 99%

“…This salt is “generally recognized as safe (GRAS)” by United States Food and Drugs Administration (USFDA) Code of Federal Regulation. Furthermore, European Food Safety Authority (EFSA) has also declared iron pyrophosphate to be a safe food additive [12]. Comparatively to conventional oral iron salts, microencapsulated liposomal iron has the highest bioavailability.…”

Section: Discussionmentioning

confidence: 99%

“…Most of these salts injure the mucosal lining of the GI tract and cause other side effects such as constipation [11]. Along with poor absorption of conventional iron, side effect profile hampers treatment compliance [12].…”

Section: Introductionmentioning

confidence: 99%

“…Gradual release helps in better absorption. This sophisticated technology of liposomal encapsulation also prevents iron to come in direct contact with intestinal mucosal lining, hence improved tolerance [12-14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of a Novel Food Supplement (Ferfer®) Containing Microencapsulated Iron in Liposomal Form in Female Iron Deficiency Anemia

Hussain

Zia

Iqbal

et al. 2019

Cureus

View full text Add to dashboard Cite

Introduction Iron deficiency anemia (IDA) is a highly afflicting condition which affects young children of growing age and reproductive age women in countries of lower economies. Conventional oral iron salts have poor absorption and gastrointestinal side effects. Microencapsulated liposomal iron pyrophosphate is a novel compound with enhanced palatability, higher bioavailability, and consequently increased adherence among people with IDA. This study aims to assess the efficacy of microencapsulated iron pyrophosphate sachets in non-pregnant women with IDA. Methods It was a 12-week long, open label clinical trial conducted with 558 IDA women. Participants were advised one sachet of microencapsulated liposomal iron pyrophosphate (Ferfer®) twice daily. At baseline, and every four-week interval, serum hemoglobin levels and taste tolerability were assessed. Data was entered and analyzed using SPSS v. 24 (IBM Corp, Armonk, NY, USA). Results Four hundred and thirty-seven women completed the trial. The mean serum Hb level at baseline was 8.71 ± 2.24 which increased to 10.47 ± 1.69 by the end of 12 weeks (p < 0.001). Conclusion Treatment of IDA with microencapsulated liposomal iron pyrophosphate sachets significantly increases serum hemoglobin levels in non-pregnant women of reproductive age.

show abstract

Expert consensus on the role of supplementation in obstetrics and gynecology using modified delphi method

Soliman,

Idris,

Momtaz

et al. 2023

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose To reach a consensus among obstetrics and gynecology experts on the effects of micronutrient supplementation on fertility and pregnancy to aid clinicians in decision-making and create a unified approach to managing micronutrient deficiencies in women, by performing a modified Delphi study. Methods A three-round modified Delphi process was conducted among a Delphi panel of 38 Egyptian experts to define recommendations regarding the role of supplementation on fertility and pregnancy in women of reproductive age. A literature review was performed and supporting evidence was graded to help guide the recommendations based on available evidence. Results A total of 62 statements were developed for discussion and voting. Out of the 62 statements, 60 statements reached expert consensus. Statements were divided into two domains. The first domain discussed the role of supplementation in fertility: optimizing natural fertility, polycystic ovary syndrome (PCOS), in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), unexplained infertility, and endometriosis, whereas the second domain was concerned with the role of supplementation in pregnancy during the prenatal, antenatal, and postnatal periods. Conclusion In this work, a modified Delphi methodology was implemented to reach a consensus on the use of micronutrient supplementation in women of reproductive age. These recommendations can help clinicians in their practice, guide future research, and identify gaps in the market for the pharmaceutical industry. This clinical guidance can be extrapolated to similar communities.

show abstract

Liposomal Iron for Iron Deficiency Anemia in Women of Reproductive Age: Review of Current Evidence

Cited by 11 publications

References 18 publications

Iron Deficiency Anemia in Pregnancy: Novel Approaches for an Old Problem

Iron Deficiency Anemia in Pregnancy: Novel Approaches for an Old Problem

Efficacy of a Novel Food Supplement (Ferfer®) Containing Microencapsulated Iron in Liposomal Form in Female Iron Deficiency Anemia

Expert consensus on the role of supplementation in obstetrics and gynecology using modified delphi method

Contact Info

Product

Resources

About